ArticleScientific reports2025
LDHA associated with telomerase-related genes promotes tumorigenesis and progression of lung adenocarcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Telomerase-related gene EHHADH drives lung cancer progression and shapes the immunosuppressive tumor microenvironment.Translational oncology · 2026Article
- LDHA, BIK, and CNIH4 Are Diagnostic Markers of Endoplasmic Reticulum Stress in Lung Cancer Comorbid With Sepsis: Integrating Machine Learning and Single-Cell Analysis of Immune Signaling.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is a lung cancer subtype with poor prognosis and high heterogeneity, posing significant challenges in clinical management. Telomerase-related genes (TRGs), crucial for chromosomal stability and tumor progression, have an unclear link to LUAD prognosis. In this study, we developed a 12-TRG-based risk model using genomic and clinical data from the TCGA and GEO databases, demonstrating high precision in predicting outcomes for patients with LUAD. We comprehensively analyzed the model's correlation with clinical features, the tumor microenvironment (TME), and drug sensitivity. Notably, in vitro experiments confirmed that LDHA knockdown reduces LUAD cell invasion, migration, and proliferation. Our findings provide new insights into the molecular mechanisms of LUAD and highlight potential therapeutic targets, thereby advancing the understanding and treatment of this aggressive cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.